Targeted Cancer Therapeutics, LLC

Investor Presentation

Table of Contents

Introduction

Technology

Efficacy

Safety

Market Size

Orphan Drug Status

Management

Valuation Analysis

Investment Opportunity

Use of Proceeds

Exit Strategy

Introduction

Targeted Cancer Therapeutics, LLC (“TCT”) is an early stage company that has developed an antibody to treat Pancreatic Cancer

Current treatment for Pancreatic Cancer does little to either alleviate patient suffering or reduce tumor size

TCT’s therapy has been clinically demonstrated to substantially reduce tumor size

Technology

CEACAM-6 is a tumor associated antigen (compound produced by tumors)

CEACAM-6 is overexpressed in 90% of all Pancreatic Cancer patients

The Anti-CEACAM-6 antibody reduces Pancreatic Cancer tumor cell vitality

This antibody binds itself to CEACAM-6, interferes with CEACAM-6’s function and causes “apoptosis” (cell death a process important in preventing tumor formation)

Efficacy of TCT’s CEACAM-6 Antibody

Anti-Ceacam 6 3mg/kg Adjusted Mean Tumor Burden BxPC3 Cells in Nude Xenograft Mice

0

200

400

600

800

1000

1200

1400

1600

1800

17 21 24 29 31 36 38 43 46 49 51 56 60 63 66 71 73 77 80

Day

Tum

or B

urde

n (m

m3)

Control n=7

Gem 150mg/kg n=8

3mg/kg n=8

Combo 3mg/kg n=7

Therapy Safety

TCT’s Anti CEACAM-6 Antibody is a highly targeted therapy for treating Pancreatic Cancer

Highly targeted therapies are inherently less toxic than traditional chemotherapy

TCT’s antibody has been demonstrated to possess little toxic side effects as a result of specifically targeting a tumor associated antigen

Market Size

Gender Diagnosed Death

Male 22,090 18,850

Female 21,830 18,540

Total 43,920 37,390

This table presents the prevalence rates of Pancreatic Cancer by gender within the United States. The Pancreatic Cancer market size is roughly 44,000 individuals with significant increases projected in the coming years. The Mortality Rate according to this data is 85%. This presents a massive unmet medical need that TCT is poised to fulfill with its Anti-CEACAM-6 antibody.

TCT’s antibody is targeting several unmet medical needs: (1) Introduce a Pancreatic Cancer therapy that dramatically reduces the size of Pancreatic Cancer tumors thereby improving treating the disease and (2) Increasing the overall quality of life for Pancreatic Cancer patients. TCT’s antibody represents a significant improvement over existing Pancreatic Cancer treatment.

Market Size

Race/Ethnicity Male Female

All Races 13.8 per 100,000 men

10.8 per 100,000 women

White 13.7 per 100,000 men

10.6 per 100,000 women

Black 17.7 per 100,000 men

14.4 per 100,000 women

Asian/Pacific Islander

10.5 per 100,000 men

8.8 per 100,000 women

American Indian 11.5 per 100,000 men

10.3 per 100,000 women

Hispanic 11.6 per 100,000 men

10.3 per 100,000 women

Incidence rates of Pancreatic Cancer for men and women in the United States. This table demonstrates the rates of Pancreatic Cancer among various gender groups within the United States. These numbers are expressed as percentages. For example, White Males accounted for 13.7% of Pancreatic Cancer cases in 2012. African American Males held the largest percentage of cases at roughly 18% of all cases.

Orphan Drug Status

“Orphan Drug” reduces the time to market which allows TCT to realize revenues sooner than most biotech's

“Orphan Drug” will increase TCT’s ability to deliver significant ROI for Series A investors

TCT will be applying for “Orphan Drug” status with the Food & Drug Administration for its Pancreatic Cancer Treatment

“Orphan Drug” status eliminates the requirement to conduct Phase 3 Clinical Trials

Management

Dr. Mahadevan, Phd/MD, Chief Scientific Officer, is a pioneer in the field of drug design and the study of pancreatic cancer. Dr. Mahadevan is a Professor of Medicine and the Director of the Phase I Program at the University of Arizona – Arizona Cancer Center.   Dr. Mahadevan’s major area of clinical interest is in the treatment and management of patients with Pancreatic cancer, Breast cancer, Gastrointestinal Stromal Tumors (GIST), Myelodysplastic Syndromes (MDS) and non-Hodgkin’s lymphoma (NHL). He is one of very few physician-scientists in the US with a Ph.D. in protein crystallography, molecular modeling and drug design who is also board certified in medical oncology.

TCT Risk Adjusted Valuation

Prec

linical

Prec

linical

2

Phas

e I

Phas

e 2

Phas

e II

FDA

0

50000000

100000000

150000000

200000000

250000000

300000000

350000000

400000000

450000000

0 12M

17M45M

90M

118M

417M

Investment Opportunity TCT has been funded to date by the founders and close

associates, but requires the following:

Round 1 funding of $2,500,000 (to be completed by the end of 2012)

Round 2 funding of $6,000,000 after IND approval (to be completed prior to the end of 2013)

Self sustaining thereafter!

TCT represents a unique investment opportunity that offers a 19% ROI in approximately 24 months

TCT’s funding requirement is so low due in part to: (1) Development costs have already been incurred; (2) Orphan Drug status so no Phase III trials and (3) TCT has the option of sub-licensing the product after Phase I trials

Use of Proceeds

TCT is anticipating the following use of proceeds following Round 1 financing:

Additional Toxicity Testing

IND Filing with the FDA

Manufacturing of the product in accordance with GMP standards

Exit Strategy

TCT has two potential exit options

(1) Out license the products to a large biotech or pharmaceutical company

(2) Deliver product to market under accelerated time line generating significant cash flow then seek a larger pharmaceutical company interested in either acquiring TCT or licensing the product from TCT

Animal Toxicity Testing of Pancreatic

Cancer Therapy (Q1-Q4)

IND Filing/Approval for Pancreatic

Cancer Therapy (Q4-Q6)

Phase I Clinical Trials of

Pancreatic Cancer Therapy

(Q6-Q10)

Milestones

Contact

If you have any additional questions or would like to discuss investing in TCT please contact Thomas Latino of Strategic Global Associates at 617-935-2588.